Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ODAC Review Of Schering-Plough’s PegIntron For Melanoma Postponed

This article was originally published in The Pink Sheet Daily

Executive Summary

Expected review of firm’s supplemental BLA for adjuvant treatment of melanoma postponed as FDA requests additional data.

You may also be interested in...



ODAC To Assess Schering's PegIntron and GSK's Votrient In October

The committee will discuss PegIntron for melanoma, and Votrient for renal cell carcinoma.

ODAC To Assess Schering's PegIntron and GSK's Votrient In October

The committee will discuss PegIntron for melanoma, and Votrient for renal cell carcinoma.

PegIntron Increases Relapse-Free Survival In Stage III Melanoma, Schering Says

U.S. approval as adjuvant therapy for melanoma has been delayed by ODAC data requests, postponed meeting.

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel